奥泰生物: 监事会关于公司2022年限制性股票激励计划首次授予第三个归属期及预留授予第二个归属期归属名单的核查意见

Core Points - The Supervisory Board of Hangzhou Aotai Biotechnology Co., Ltd. has reviewed and approved the list of beneficiaries for the third vesting period of the 2022 restricted stock incentive plan and the second vesting period of the reserved grant [1][2] - A total of 94 beneficiaries are proposed for the third vesting period and 18 beneficiaries for the second vesting period, all of whom meet the qualifications set forth in relevant laws and regulations [1][2] Summary by Sections - Regulatory Compliance: The incentive plan adheres to the Company Law, Securities Law, and other relevant regulations, confirming the legality and validity of the beneficiaries' qualifications [1] - Beneficiary Eligibility: The proposed beneficiaries for both vesting periods fulfill the conditions outlined in the incentive plan draft and are deemed eligible to receive restricted stock [1] - Approval Process: The Supervisory Board has formally agreed to the beneficiary list for the incentive plan, indicating a structured approval process [2]